中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
5期
612-614
,共3页
吴玉华%翁琳%曾思文%陈左平%熊爱华
吳玉華%翁琳%曾思文%陳左平%熊愛華
오옥화%옹림%증사문%진좌평%웅애화
肺疾病,慢性阻塞性%辛伐他汀%沙美特罗替卡松
肺疾病,慢性阻塞性%辛伐他汀%沙美特囉替卡鬆
폐질병,만성조새성%신벌타정%사미특라체잡송
Pulmonary disease,chronic obstructive%Simvastatin%Salmeterol fluticasone
目的 探讨辛伐他汀联合沙美特罗替卡松粉吸入剂对慢性阻塞性肺疾病(COPD)肺功能的影响.方法 选择临床确诊的COPD患者200例,根据治疗方法的不同分为对照组(32例)、辛伐他汀组、吸入剂组及联合组,后3组各56例.通过生活质量评估问卷(CAT)评分、测肺功能、血气分析指标和C反应蛋白(CRP)的动态改变,比较不同治疗方法对COPD患者肺功能的影响.结果 辛伐他汀组、吸入剂组、联合组患者治疗后CAT评分[(24±4)、(24±4)和(19±3)分]、PaCO2[(50±6)、(50±6)和(48±6)mm Hg(1 mm Hg=0.133 kPa)]、CRP[(25±9)、(26±9)和(18±6) mg/L]明显低于治疗前[CAT评分:(27±5)、(27±5)和(27±5)分,PaCO2:(54±8)、(54±7)和(546)mm Hg,CRP:(39±10)、(39±10)和(39±10) mg/L] (P ＜0.05).治疗后,联合组患者CAT评分、PaCO2、CRP均低于辛伐他汀组和吸入剂组(P＜0.05).辛伐他汀组、吸入剂组、联合组患者治疗后用力肺活量(FVC)[(2.3±0.4)、(2.3±0.4)和(2.5±0.5)L]、第1秒用力呼气容积(FEV1)[(1.4±0.4)、(1.4±0.4)和(1.7±0.5)L]、第1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)[(1.4±0.4)、(1.4±0.4)和(1.7±0.5)％]、PaO2[(68±8)、(68±8)和(72±8)mm Hg]均较高于治疗前[FVC:(2.1±0.4)、(2.1 ±0.4)和(2.1±0.4)L,FEV1:(1.2±0.3)、(1.2±0.3)和(1.3±0.3)L,FEV1/FVC:(68±9)、(66±9)和(67±9)％,PaO2:(63 ±7)、(64±8)和(64±8)mm Hg](P＜0.05).治疗后,联合组患者FVC、FEV1、FEV1/FVC、PaO2高于辛伐他汀组和吸入剂组(P＜0.05).结论 辛伐他汀联合沙美特罗替卡松粉吸入剂治疗可改善COPD患者肺功能、血气分析指标,减轻呼吸困难.
目的 探討辛伐他汀聯閤沙美特囉替卡鬆粉吸入劑對慢性阻塞性肺疾病(COPD)肺功能的影響.方法 選擇臨床確診的COPD患者200例,根據治療方法的不同分為對照組(32例)、辛伐他汀組、吸入劑組及聯閤組,後3組各56例.通過生活質量評估問捲(CAT)評分、測肺功能、血氣分析指標和C反應蛋白(CRP)的動態改變,比較不同治療方法對COPD患者肺功能的影響.結果 辛伐他汀組、吸入劑組、聯閤組患者治療後CAT評分[(24±4)、(24±4)和(19±3)分]、PaCO2[(50±6)、(50±6)和(48±6)mm Hg(1 mm Hg=0.133 kPa)]、CRP[(25±9)、(26±9)和(18±6) mg/L]明顯低于治療前[CAT評分:(27±5)、(27±5)和(27±5)分,PaCO2:(54±8)、(54±7)和(546)mm Hg,CRP:(39±10)、(39±10)和(39±10) mg/L] (P ＜0.05).治療後,聯閤組患者CAT評分、PaCO2、CRP均低于辛伐他汀組和吸入劑組(P＜0.05).辛伐他汀組、吸入劑組、聯閤組患者治療後用力肺活量(FVC)[(2.3±0.4)、(2.3±0.4)和(2.5±0.5)L]、第1秒用力呼氣容積(FEV1)[(1.4±0.4)、(1.4±0.4)和(1.7±0.5)L]、第1秒用力呼氣容積佔用力肺活量百分比(FEV1/FVC)[(1.4±0.4)、(1.4±0.4)和(1.7±0.5)％]、PaO2[(68±8)、(68±8)和(72±8)mm Hg]均較高于治療前[FVC:(2.1±0.4)、(2.1 ±0.4)和(2.1±0.4)L,FEV1:(1.2±0.3)、(1.2±0.3)和(1.3±0.3)L,FEV1/FVC:(68±9)、(66±9)和(67±9)％,PaO2:(63 ±7)、(64±8)和(64±8)mm Hg](P＜0.05).治療後,聯閤組患者FVC、FEV1、FEV1/FVC、PaO2高于辛伐他汀組和吸入劑組(P＜0.05).結論 辛伐他汀聯閤沙美特囉替卡鬆粉吸入劑治療可改善COPD患者肺功能、血氣分析指標,減輕呼吸睏難.
목적 탐토신벌타정연합사미특라체잡송분흡입제대만성조새성폐질병(COPD)폐공능적영향.방법 선택림상학진적COPD환자200례,근거치료방법적불동분위대조조(32례)、신벌타정조、흡입제조급연합조,후3조각56례.통과생활질량평고문권(CAT)평분、측폐공능、혈기분석지표화C반응단백(CRP)적동태개변,비교불동치료방법대COPD환자폐공능적영향.결과 신벌타정조、흡입제조、연합조환자치료후CAT평분[(24±4)、(24±4)화(19±3)분]、PaCO2[(50±6)、(50±6)화(48±6)mm Hg(1 mm Hg=0.133 kPa)]、CRP[(25±9)、(26±9)화(18±6) mg/L]명현저우치료전[CAT평분:(27±5)、(27±5)화(27±5)분,PaCO2:(54±8)、(54±7)화(546)mm Hg,CRP:(39±10)、(39±10)화(39±10) mg/L] (P ＜0.05).치료후,연합조환자CAT평분、PaCO2、CRP균저우신벌타정조화흡입제조(P＜0.05).신벌타정조、흡입제조、연합조환자치료후용력폐활량(FVC)[(2.3±0.4)、(2.3±0.4)화(2.5±0.5)L]、제1초용력호기용적(FEV1)[(1.4±0.4)、(1.4±0.4)화(1.7±0.5)L]、제1초용력호기용적점용력폐활량백분비(FEV1/FVC)[(1.4±0.4)、(1.4±0.4)화(1.7±0.5)％]、PaO2[(68±8)、(68±8)화(72±8)mm Hg]균교고우치료전[FVC:(2.1±0.4)、(2.1 ±0.4)화(2.1±0.4)L,FEV1:(1.2±0.3)、(1.2±0.3)화(1.3±0.3)L,FEV1/FVC:(68±9)、(66±9)화(67±9)％,PaO2:(63 ±7)、(64±8)화(64±8)mm Hg](P＜0.05).치료후,연합조환자FVC、FEV1、FEV1/FVC、PaO2고우신벌타정조화흡입제조(P＜0.05).결론 신벌타정연합사미특라체잡송분흡입제치료가개선COPD환자폐공능、혈기분석지표,감경호흡곤난.
Objective To investigate the effects of simvastatin and salmeterol fluticasone propionate powder inhalation for chronic obstructive pulmonary disease (COPD) on pulmonary function.Methods All 200 cases of COPD were divided into control group (32 cases),simvastatin,inhalation group and combination group,3 groups of 56 patients each.Using quality of life assessment questionnaire (CAT) score,by monitoring of pulmonary function,blood gas analysis and C-reactive protein (CRP) changes,comparison of different treatment methods for 4 sets of COPD change of pulmonary function of patients with COPD.Results The simvastatin group,inhalation group,united group therapy for patients with scores of CAT score [(24 ±4),(24 ±4) and (19 ±3) scores],carbon dioxide partial pressure (PaCO2) [(50 ± 6),(50 ± 6) and (48 ± 6) mm Hg,CRP [(25 ± 9),(26 ± 9) and (18 ±6) mg/L] was significantly lower than that before treatment [CAT score:(27 ±5),(27 ±5) and (27 ±5)scores,PaCO2:(54±8),(54±7) and (54±6) mm Hg,CRP:(39±10),(39±10) and (39±10) mg/L],group differences were statistically significant (P ＜ 0.05).After treatment,the group of patients with CAT score,PaCO2,CRP were lower than those of the simvastatin and inhalation group,the difference between groups was statistically significant (P ＜ 0.05).Simvastatin group,inhalation group,united group patients after forced vital capacity (FVC) [(2.3 ± 0.4),(2.3 ± 0.4) and (2.5 ± 0.5) L],forced expiratory volume in one second (FEV1) [(1.4 ± 0.4),(1.4 ± 0.4) L and (1.7 ± 0.5) L],forced expiratory second rate (FEV1/FVC) [(1.4 ± 0.4),(1.4 ± 0.4) and (1.7 ± 0.5) ％,PaO2 [(68 ± 8),(68 ± 8) and (72 ± 8) mm Hg] were higher than those before treatment [FVC:(2.1± 0.4),(2.1 ±0.4)Land (2.1±0.4) L,FEV1:(1.2±0.3),(1.2±0.3)L and (1.3±0.3) L,FEV1/FVC:(68 ±9),(66±9) and (67±9) ％,PaO2:(63 ±7),(64±8) and (64±8) mm Hg],group differences were statistically significant (P ＜0.05).After treatment,the group of patients with FVC,FEV1,FEV1/FVC,PaO2 higher than that of the simvastatin and inhalation group,the difference between groups was statistically significant (P ＜ 0.05).Conclusion Simvastatin combined with salmeterol fluticasone propionate powder for inhalation therapy can improve pulmonary function,blood gas analysis in patients with COPD.
